Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany

This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival model to compare medical costs and treatment effectiveness for patients with such cancers over 45 months. Transition probabilities were derived from survival data from a randomized Phase-III EMBRACA trial, utilities based on published reports, and costs in Euros, which included costs for drug acquisition, clinical monitoring, and treatment of adverse events. Willingness-to-pay thresholds were set to be multiples of the current German per capita gross domestic product. Treatment with talazoparib led to a gain of 0.32 life-years (0.22 quality-adjusted life-years). The mean total cost of Euro84,003 for talazoparib and Euro12,741 for standard therapy resulted in an incremental cost-effectiveness ratio of Euro223,246 per life-year and Euro323,932 per quality-adjusted life-year gained, indicating that talazoparib is unlikely to be cost-effective at current pricing.

Automated summary

This study evaluated the cost-effectiveness factors of talazoparib for patients with a germline breast-cancer-gene (brca) mutation and locally advanced or metastasized breast cancer in the German healthcare system. The findings suggest that talazoparib is not cost-effective at current pricing.